ASCO 2022 Conference Coverage

 

Leukemia
47

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Efficacy & Safety Results From the Phase 3 ASCEMBL Study of Asciminib vs. Bosutinib in CP-CML After ≥2 Prior TKIs: Week 96 Update

FEATURING Jorge Cortés
  • 20 views
  • July 12, 2022
11:45

ASCO 2022 Conference Coverage

ASCO 2022 Efficacy & Safety Results From the Phase 3 ASCEMBL Study of Asciminib vs. Bosutinib in CP-CML After ≥2 Prior TKIs: Week 96 Update

FEATURING Jorge Cortés
  • 267 views
  • July 12, 2022
  • 2
02:16

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Overall Survival by IDH2 Mutant Allele (R140 or R172) in Late-Stage Mutant-IDH2 R/R AML Treated With Enasidenib or Conventional Care Regimens in the Phase 3 IDHENTIFY Trial

FEATURING Stéphane De Botton
  • 11 views
  • July 9, 2022
08:40

ASCO 2022 Conference Coverage

ASCO 2022 on Overall Survival by IDH2 Mutant Allele (R140 or R172) in Late-Stage Mutant-IDH2 R/R AML Treated With Enasidenib or Conventional Care Regimens in the Phase 3 IDHENTIFY Trial

FEATURING Stéphane De Botton
  • 17 views
  • July 9, 2022
07:21

ASCO 2022 Conference Coverage

ASCO 2022 Updated Results From a Phase II Study of mini-HCVD + Ino +/- Blina in Older Adults With Newly Diagnosed Ph- B-Cell ALL

FEATURING Walid Macaron
  • 74 views
  • June 28, 2022
06:33

ASCO 2022 Conference Coverage

ASCO 2022 Treatment-Free Remission in CML Patients Following the Discontinuation of Tyrosine Kinase Inhibitors

FEATURING Fadi Haddad
  • 141 views
  • June 28, 2022
36

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Treatment-Free Remission in CML Patients Following the Discontinuation of Tyrosine Kinase Inhibitors

FEATURING Fadi Haddad
  • 11 views
  • June 28, 2022
56

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updates on the Evolution of Asparaginase in the Management of ALL

FEATURING Ryan Cassaday
  • 18 views
  • June 28, 2022
06:42

ASCO 2022 Conference Coverage

ASCO 2022 Updates on the Evolution of Asparaginase in the Management of ALL

FEATURING Ryan Cassaday
  • 356 views
  • June 28, 2022
  • 1
01:53

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Leveraging AML Genomics Across the Therapeutic Spectrum

FEATURING Gabriel Mannis
  • 10 views
  • June 21, 2022
03:47

ASCO 2022 Conference Coverage

ASCO 2022 on a Phase 1b Study of Blinatumomab With the Anti-Programmed Cell Death PD-1 Antibody AMG 404 in Adults With R/R B-Cell Precursor ALL

FEATURING Cristina Papayannidis
  • 13 views
  • June 17, 2022
55

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on a Phase 1b Study of Blinatumomab With the Anti-Programmed Cell Death PD-1 Antibody AMG 404 in Adults With R/R B-Cell Precursor ALL

FEATURING Cristina Papayannidis
  • 7 views
  • June 17, 2022
06:50

ASCO 2022 Conference Coverage

ASCO 2022 on a Phase II Study of Hyper-CVAD With Sequential Blina +/- Inotuzumab Ozogamicin in Adults With Newly Diagnosed B-Cell ALL

FEATURING Nicholas Short
  • 24 views
  • June 15, 2022
01:09

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on a Phase II Study of Hyper-CVAD With Sequential Blina +/- Inotuzumab Ozogamicin in Adults With Newly Diagnosed B-Cell ALL

FEATURING Nicholas Short
  • 13 views
  • June 15, 2022
03:56

ASCO 2022 Conference Coverage

ASCO 2022 Bosutinib in Newly Diagnosed CML: Gastrointestinal, Liver, Effusion, and Renal Safety Characterization in the BFORE Trial

FEATURING Jorge Cortés
  • 81 views
  • June 15, 2022
36

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Bosutinib in Newly Diagnosed CML: Gastrointestinal, Liver, Effusion, and Renal Safety Characterization in the BFORE Trial

FEATURING Jorge Cortés
  • 11 views
  • June 15, 2022
06:30

ASCO 2022 Conference Coverage

ASCO 2022 Efficacy and Safety of Bosutinib in Later-Line Patients With CML: A Sub-Analysis From the Phase 4 BYOND Trial

FEATURING Carlo Gambacorti-Passerini
  • 48 views
  • June 9, 2022